Design and In Silico and In Vitro Evaluations of a Novel Nicotinamide Derivative as a VEGFR-2 Inhibitor

Table 4

Computational toxicity profile of the targeted nicotinamide derivative.

Toxicity parameters	The targeted nicotinamide derivative	Sorafenib
Ames mutagenicity prediction	No
FDA rodent carcinogenicity in male rats	No
Developmental toxicity	Safe	Toxic
Carcinogenic potency TD50 in rats	45.37 mg.kg^−1/day	14.24 mg.kg^−1/day
Maximum tolerated feeding dose in rats	0.12 g.kg^−1	0.09 g.kg^−1
Oral LD50 in rats	2.81 g.kg^−1	0.82 g.kg^−1
Chronic LOAEL in rats	0.34 g.kg^−1	0.005 g.kg^−1
Ocular irritation	Mild
Dermal irritation	No irritation